Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation

被引:60
作者
Lappegård, KT [1 ]
Fung, M
Bergseth, G
Riesenfeld, J
Lambris, JD
Videm, V
Mollnes, TE
机构
[1] Nordland Hosp, Dept Med, N-8092 Bodo, Norway
[2] Nordland Hosp, Dept Immunol, N-8092 Bodo, Norway
[3] Nordland Hosp, Dept Transfus Med, N-8092 Bodo, Norway
[4] Tanox Biosyst Inc, Houston, TX 77025 USA
[5] Univ Tromso, Tromso, Norway
[6] Carmeda AB, Stockholm, Sweden
[7] Univ Penn, Dept Pathol & Lab Med, Prot Chem Lab, Philadelphia, PA 19104 USA
[8] Univ Trondheim Hosp, Dept Immunol & Transfus Med, N-7006 Trondheim, Norway
[9] Norwegian Univ Sci & Technol, Inst Lab Med, N-7006 Trondheim, Norway
[10] Aker Univ Hosp, Rikshosp, Inst Immunol, Oslo, Norway
关键词
D O I
10.1016/S0003-4975(03)01519-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Exposure of blood to artificial surfaces, as in cardiopulmonary bypass, induces an inflammatory response involving complement, leukocyte and platelet activation. To elucidate the specific role of complement in this process, studies were performed on blood circulated in polyvinyl chloride tubing in the absence and presence of complement inhibitors. Parallel experiments were performed with heparin-coated polyvinyl chloride tubing, which is known to prevent complement and cell activation. Methods. A novel experimental model was used, based on human whole blood anticoagulated with lepirudin. Complement activation products, myeloperoxidase, lactoferrin, and thrombospondin were quantified in enzyme immunoassays. Leukocyte CD11b expression and leukocyte-platelet conjugates were detected by flow cytometry. Results. Increased levels of C3 activation products, alternative pathway convertase, and the terminal SC5b-9 complex, combined with unchanged levels of C1rs-C1-inhibitor complexes and marginal changes in C4 activation demonstrated that complement was activated through the alternative pathway. Granulocyte and monocyte CD11b expression and granulocyte-platelet conjugate formation were efficiently attenuated by blocking either factor D, C3, C5, or C5a receptor. In contrast, monocyte-platelet conjugate formation and release of myeloperoxidase, lactoferrin, and thrombospondin were not reduced by complement inhibition. Heparin-coated polyvinyl chloride tubing efficiently reduced all inflammatory markers studied, except for C1rs-C1-inhibitor complexes, which increased, consistent with the enhancing effect of heparin on Cl-inhibitor function. This effect did not, however, reduce fluid-phase classic pathway activation induced by heat-aggregated immunoglobulin G. Conclusions. Leukocyte and platelet activation in response to artificial materials occur by mechanisms that vary in their dependence on complement. Heparin coating precludes both the complement-dependent and complement-independent reactions. (C) 2004 by The Society of Thoracic Surgeons.
引用
收藏
页码:932 / 941
页数:10
相关论文
共 44 条
[11]   Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a [J].
Finch, AM ;
Wong, AK ;
Paczkowski, NJ ;
Wadi, SK ;
Craik, DJ ;
Fairlie, DP ;
Taylor, SM .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (11) :1965-1974
[12]   Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass [J].
Fitch, JCK ;
Rollins, S ;
Matis, L ;
Alford, B ;
Aranki, S ;
Collard, CD ;
Dewar, M ;
Elefteriades, J ;
Hines, R ;
Kopf, G ;
Kraker, P ;
Li, L ;
O'Hara, R ;
Rinder, C ;
Rinder, H ;
Shaw, R ;
Smith, B ;
Stahl, G ;
Shernan, SK .
CIRCULATION, 1999, 100 (25) :2499-2506
[13]   Inhibition of complement neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits [J].
Fung, M ;
Loubser, PG ;
Ündar, A ;
Mueller, M ;
Sun, C ;
Sun, WN ;
Vaughn, WK ;
Fraser, CD .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (01) :113-122
[14]   A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s [J].
Fure, H ;
Nielsen, EW ;
Hack, CE ;
Mollnes, TE .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1997, 46 (06) :553-557
[15]  
Garred P, 1997, ARTIF ORGANS, V21, P293
[16]   QUANTIFICATION IN ENZYME-LINKED IMMUNOSORBENT-ASSAY OF A C-3 NEOEPITOPE EXPRESSED ON ACTIVATED HUMAN-COMPLEMENT FACTOR-C3 [J].
GARRED, P ;
MOLLNES, TE ;
LEA, T .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1988, 27 (03) :329-335
[17]   Biomaterial development for cardiopulmonary bypass [J].
Gourlay, T .
PERFUSION-UK, 2001, 16 (05) :381-390
[18]   AN ENZYME LINKED IMMUNOSORBENT-ASSAY FOR MEASUREMENTS OF LACTOFERRIN IN DUODENAL ASPIRATES AND OTHER BIOLOGICAL-FLUIDS [J].
HEGNHOJ, J ;
DEMUCKADELL, OBS .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1985, 45 (06) :489-495
[19]   A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation acid the effect of aspirin [J].
Hong, J ;
Ekdahl, KN ;
Reynolds, H ;
Larsson, R ;
Nilsson, B .
BIOMATERIALS, 1999, 20 (07) :603-611
[20]   PLASMA-LEVELS OF MAIN GRANULOCYTE COMPONENTS DURING HEMODIALYSIS - COMPARISON OF NEW AND REUSED DIALYZERS [J].
HORL, WH ;
FEINSTEIN, EI ;
WANNER, C ;
FRISCHMUTH, N ;
GOSELE, A ;
MASSRY, SG .
AMERICAN JOURNAL OF NEPHROLOGY, 1990, 10 (01) :53-57